French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp. with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group’s drugs, the companies said.
*For more on this story, read the full Reuters article.
